CASIA OpenIR
Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
Sun, Ting1,2; Zhang, Wenjia1,2; Li, Yuan1; Jin, Zhengyu1; Du, Yang2,3; Tian, Jie2,3; Xue, Huadan1
Source PublicationMOLECULAR CANCER THERAPEUTICS
ISSN1535-7163
2020-03-01
Volume19Issue:3Pages:802-811
Corresponding AuthorDu, Yang(yang.du@ia.ac.cn) ; Tian, Jie(jie.tian@ia.ac.cn) ; Xue, Huadan(bjdanna95@hotmail.com)
AbstractPostoperative tumor recurrence and metastasis remain an extreme challenge in breast cancer. Therapies that target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have provided unprecedented clinical benefits in various types of cancer. The aim of this study was to determine whether the combination of anti-CTLA-4 and anti-PD-1 could prevent postoperative breast tumor recurrence and metastasis in breast tumor-bearing mice. 1'he results indicated that the combination of CTLA-4 and PD-1 inhibitors was more effective compared with single inhibitors for mammary tumor growth and prevention of postsurgical tumor recurrence and pulmonary metastasis (P < 0.05), which resulted in prolonged survival (P < 0.05). Analysis of the underlying mechanism revealed that anti-CTLA-4 and anti-PD-1 in combination synergistically promoted the infiltration of CD8+ and CD4+ T cells into tumors (P < 0.05 vs. single inhibitors), thus boosting the antitumor immune responses. In summary, our results revealed that combination immunotherapy with anti-CTLA-4 and anti-PD-1 may present a new, promising regimen to inhibit postoperative breast cancer relapse and lung metastasis and improve patient outcomes, which warrants further investigation in clinical settings.
DOI10.1158/1535-7163.MCT-19-0495
WOS KeywordIMMUNE CHECKPOINT INHIBITORS ; CARCINOMA IN-SITU ; INFILTRATING LYMPHOCYTES ; COMBINED NIVOLUMAB ; ADVERSE EVENTS ; PD-1 BLOCKADE ; CANCER ; SURVIVAL ; PEMBROLIZUMAB ; IPILIMUMAB
Indexed BySCI
Language英语
Funding ProjectNational Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81371608] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Beijing Natural Science Foundation[7172170] ; National Public Welfare Basic Scientific Research Project[2017PT32004] ; Chinese Academy of Medical Sciences Students' Innovation Foundation[1007-1002-1-12] ; National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81371608] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Beijing Natural Science Foundation[7172170] ; National Public Welfare Basic Scientific Research Project[2017PT32004] ; Chinese Academy of Medical Sciences Students' Innovation Foundation[1007-1002-1-12]
Funding OrganizationNational Key Research and Development Plan of China ; National Natural Science Foundation of China ; Beijing Natural Science Foundation ; National Public Welfare Basic Scientific Research Project ; Chinese Academy of Medical Sciences Students' Innovation Foundation
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000518190200007
PublisherAMER ASSOC CANCER RESEARCH
Citation statistics
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/38432
Collection中国科学院自动化研究所
Corresponding AuthorDu, Yang; Tian, Jie; Xue, Huadan
Affiliation1.Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China
2.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing, Peoples R China
3.Univ Chinese Acad Sci, Beijing, Peoples R China
First Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Recommended Citation
GB/T 7714
Sun, Ting,Zhang, Wenjia,Li, Yuan,et al. Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis[J]. MOLECULAR CANCER THERAPEUTICS,2020,19(3):802-811.
APA Sun, Ting.,Zhang, Wenjia.,Li, Yuan.,Jin, Zhengyu.,Du, Yang.,...&Xue, Huadan.(2020).Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.MOLECULAR CANCER THERAPEUTICS,19(3),802-811.
MLA Sun, Ting,et al."Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis".MOLECULAR CANCER THERAPEUTICS 19.3(2020):802-811.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Sun, Ting]'s Articles
[Zhang, Wenjia]'s Articles
[Li, Yuan]'s Articles
Baidu academic
Similar articles in Baidu academic
[Sun, Ting]'s Articles
[Zhang, Wenjia]'s Articles
[Li, Yuan]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Sun, Ting]'s Articles
[Zhang, Wenjia]'s Articles
[Li, Yuan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.